TW200633998A - Substituted heterocyclic compounds and thrombopoietin receptor activators - Google Patents

Substituted heterocyclic compounds and thrombopoietin receptor activators

Info

Publication number
TW200633998A
TW200633998A TW094143200A TW94143200A TW200633998A TW 200633998 A TW200633998 A TW 200633998A TW 094143200 A TW094143200 A TW 094143200A TW 94143200 A TW94143200 A TW 94143200A TW 200633998 A TW200633998 A TW 200633998A
Authority
TW
Taiwan
Prior art keywords
sup
substituted heterocyclic
heterocyclic compounds
thrombopoietin receptor
receptor activators
Prior art date
Application number
TW094143200A
Other languages
Chinese (zh)
Inventor
Katsuaki Miyaji
Shunsuke Iwamoto
Hirofumi Ota
Yukihiro Shigeta
Yutaka Hirokawa
Satoshi Nakano
Norihisa Ishiwata
Original Assignee
Nissan Chemical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nissan Chemical Ind Ltd filed Critical Nissan Chemical Ind Ltd
Publication of TW200633998A publication Critical patent/TW200633998A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The present invention provides compounds which can improve, prevent or cure diseases by activating the thrombopoietin receptors. These compounds are: the compounds represented by the formula (1) (wherein A, B, R.sup.1, L.sup.1, R.sup.2, L.sup.2, L.sup.3, Y, L.sup.4, R.sup.3, and X are defined in the text), their tautomers, prodrugs or their pharmaceutically acceptable salts or their solvates.
TW094143200A 2004-12-08 2005-12-07 Substituted heterocyclic compounds and thrombopoietin receptor activators TW200633998A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2004355079 2004-12-08

Publications (1)

Publication Number Publication Date
TW200633998A true TW200633998A (en) 2006-10-01

Family

ID=36578053

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094143200A TW200633998A (en) 2004-12-08 2005-12-07 Substituted heterocyclic compounds and thrombopoietin receptor activators

Country Status (3)

Country Link
JP (1) JPWO2006062247A1 (en)
TW (1) TW200633998A (en)
WO (1) WO2006062247A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1947101A4 (en) 2005-11-07 2009-09-16 Nissan Chemical Ind Ltd Hydrazide compound and thrombopoietin receptor activator
EP2228434A4 (en) * 2007-12-05 2013-01-23 Nissan Chemical Ind Ltd Amplification method for hematopoietic stem cells with heterocyclic compound
WO2009072626A1 (en) * 2007-12-05 2009-06-11 Nissan Chemical Industries, Ltd. Method for amplification of hematopoietic stem cell using heterocyclic compound
EP2228435A4 (en) * 2007-12-05 2013-01-23 Nissan Chemical Ind Ltd Method for amplification of hematopoietic stem cell using heterocyclic compound
US9527828B2 (en) * 2007-12-06 2016-12-27 Nissan Chemical Industries, Ltd. Method for expanding hematopoietic stem cells using heterocyclic compound
RU2485112C1 (en) * 2012-04-26 2013-06-20 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Пермский государственный национальный исследовательский университет" 4-(4-bromophenyl)-4-oxo-2-{[3-ethoxycarbonyl)-4,5-dimethylthien-2-yl]amino}-2-butenoic acid, having anti-inflammatory and analgesic activity

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6350771B1 (en) * 1996-12-24 2002-02-26 Rhone-Poulenc, Inc. Pesticidal 1-arylpyrazoles
JP3786578B2 (en) * 1997-11-18 2006-06-14 帝人ファーマ株式会社 Cyclic amine derivatives and their use as pharmaceuticals
ATE308985T1 (en) * 1999-05-18 2005-11-15 Teijin Ltd REMEDIES AND PREVENTION FOR CHEMOKINE-RELATED DISEASES
JP2003513965A (en) * 1999-11-05 2003-04-15 スミスクライン・ビーチャム・コーポレイション Semicarbazone derivatives and their use as thrombopoietin mimetics
AU2002239718A1 (en) * 2000-12-19 2002-07-01 Ligand Pharmaceuticals Thrombopoietin mimetics
JP2005517635A (en) * 2001-11-07 2005-06-16 フュアエスツェー アクチェンゲゼルシャフト Selective antibacterial agent
UA82695C2 (en) * 2003-06-06 2008-05-12 Нисан Кемикал Индастриз, Лтд. Heteroaromatic compounds as thrombopoietin receptor activators

Also Published As

Publication number Publication date
WO2006062247A1 (en) 2006-06-15
JPWO2006062247A1 (en) 2008-06-12

Similar Documents

Publication Publication Date Title
TW200633984A (en) Amide compounds and activators of thrombopoietin receptor
MX2009003038A (en) 5-substituted quinazolinone derivatives and compositions comprising and methods of using the same.
SG164288A1 (en) Chemokine receptor antagonists
TW200728298A (en) Thiophene compounds and thrombopoietin receptor activators
TW200633712A (en) Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof
RS92004A (en) Pyrrolo-triazine aniline compounds useful as kinase inhibitors
TW200626145A (en) Heterocyclic compounds and thrombopoietin receptor activators
MXPA05012248A (en) Phenyl quinolines and their use as estrogen receptor modulators.
UA97976C2 (en) 4'-o-substituted isoindoline derivatives and compositions comprising and methods of using the same
WO2007117465A3 (en) Indazole compounds
TW200613302A (en) Nk1 antagonists
NO20076418L (en) Heterocyclic compounds as agonists for the thyroid receptor
TW200744588A (en) Pharmaceutical composition for external use
TW200745056A (en) Diaminopyrimidines as P2X3 and P2X2/3 modulators
NZ588121A (en) Novel estrogen receptor ligands
TW200612925A (en) Prodrug substituted benzoxazoles as estrogenic agents
IL205354A0 (en) Spiroindolinone derivatives
ATE553106T1 (en) HETEROARYLPYRROLOPYRIDINONES AS KINASE INHIBITORS
TW200727920A (en) New regimens for oral monophasic contraceptives
TNSN08191A1 (en) Kinase inhibitors
NO20090779L (en) 5,6-Bisaryl-2-pyridine carboxamide derivatives, preparation and use thereof in therapeutics such as urethosine II receptor antagonists
TW200633998A (en) Substituted heterocyclic compounds and thrombopoietin receptor activators
HK1145172A1 (en) (aza)indole derivative substituted in position 5, pharmaceutical composition comprising it, intermediate compounds and preparation process therefor
TW200633997A (en) Substituted heterocyclic compounds and thrombopoietin receptor activators
ZA200801332B (en) Pentacyclic kinase inhibitors